| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dacarbazine | 4 | 2004 | 559 | 0.390 |
Why?
|
| Neoplasms | 44 | 2008 | 22140 | 0.380 |
Why?
|
| Camptothecin | 9 | 2007 | 591 | 0.370 |
Why?
|
| Antineoplastic Agents | 23 | 2007 | 13632 | 0.350 |
Why?
|
| Antineoplastic Agents, Phytogenic | 11 | 2008 | 620 | 0.330 |
Why?
|
| Quinazolines | 6 | 2006 | 1371 | 0.320 |
Why?
|
| HLA-B Antigens | 3 | 2003 | 317 | 0.300 |
Why?
|
| Oligopeptides | 4 | 2006 | 1179 | 0.290 |
Why?
|
| Antineoplastic Agents, Alkylating | 5 | 2004 | 617 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2007 | 11733 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 34 | 2006 | 10756 | 0.260 |
Why?
|
| Depsipeptides | 2 | 2006 | 95 | 0.260 |
Why?
|
| Rifabutin | 1 | 2004 | 59 | 0.230 |
Why?
|
| Carmustine | 1 | 2004 | 137 | 0.230 |
Why?
|
| Immunogenetics | 1 | 2003 | 62 | 0.230 |
Why?
|
| Maximum Tolerated Dose | 16 | 2008 | 883 | 0.220 |
Why?
|
| Molecular Probe Techniques | 1 | 2004 | 111 | 0.220 |
Why?
|
| Area Under Curve | 14 | 2006 | 1636 | 0.210 |
Why?
|
| Neutropenia | 10 | 2006 | 885 | 0.200 |
Why?
|
| Topotecan | 2 | 2000 | 131 | 0.190 |
Why?
|
| Infusions, Intravenous | 15 | 2008 | 2217 | 0.180 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 1123 | 0.170 |
Why?
|
| Carbamates | 1 | 2001 | 191 | 0.170 |
Why?
|
| Drug Design | 1 | 2003 | 1045 | 0.150 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1998 | 94 | 0.150 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 1998 | 70 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2004 | 1624 | 0.140 |
Why?
|
| Sesquiterpenes | 3 | 2004 | 176 | 0.140 |
Why?
|
| Etoposide | 1 | 1998 | 635 | 0.140 |
Why?
|
| Paclitaxel | 7 | 2006 | 1730 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2001 | 858 | 0.130 |
Why?
|
| Thionucleotides | 2 | 2005 | 107 | 0.120 |
Why?
|
| Maytansine | 2 | 2008 | 86 | 0.120 |
Why?
|
| Guanine | 2 | 2007 | 278 | 0.120 |
Why?
|
| Glutamates | 2 | 2007 | 385 | 0.120 |
Why?
|
| Drug Administration Schedule | 15 | 2006 | 4851 | 0.120 |
Why?
|
| Administration, Oral | 10 | 2004 | 4015 | 0.110 |
Why?
|
| Cholestanols | 2 | 2003 | 8 | 0.110 |
Why?
|
| Enzyme Inhibitors | 5 | 2004 | 3702 | 0.110 |
Why?
|
| Aminoglycosides | 2 | 2005 | 160 | 0.110 |
Why?
|
| Cisplatin | 3 | 2005 | 1652 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2006 | 646 | 0.100 |
Why?
|
| HLA-A Antigens | 2 | 2003 | 223 | 0.100 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2005 | 457 | 0.100 |
Why?
|
| Genes, p53 | 2 | 2006 | 713 | 0.090 |
Why?
|
| Half-Life | 5 | 2008 | 649 | 0.090 |
Why?
|
| Drug Interactions | 6 | 2007 | 1417 | 0.090 |
Why?
|
| Hematologic Diseases | 6 | 2008 | 496 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2004 | 3534 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 4 | 2006 | 362 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2006 | 2047 | 0.080 |
Why?
|
| Taxoids | 2 | 2004 | 668 | 0.080 |
Why?
|
| Aged | 48 | 2008 | 169288 | 0.080 |
Why?
|
| Prodrugs | 2 | 2002 | 262 | 0.080 |
Why?
|
| Medical Records | 1 | 2014 | 1409 | 0.080 |
Why?
|
| Drug Resistance, Multiple | 2 | 2001 | 255 | 0.080 |
Why?
|
| Middle Aged | 51 | 2014 | 220853 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2004 | 6585 | 0.070 |
Why?
|
| Adult | 49 | 2008 | 221119 | 0.070 |
Why?
|
| Nausea | 7 | 2006 | 678 | 0.070 |
Why?
|
| Venous Thrombosis | 2 | 2014 | 1304 | 0.070 |
Why?
|
| Pyridines | 3 | 2004 | 2872 | 0.070 |
Why?
|
| Indoles | 2 | 2006 | 1830 | 0.070 |
Why?
|
| Apoptosis | 2 | 2001 | 9477 | 0.060 |
Why?
|
| Models, Chemical | 5 | 2005 | 609 | 0.060 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2004 | 17 | 0.060 |
Why?
|
| Male | 50 | 2008 | 360693 | 0.060 |
Why?
|
| Bibenzyls | 1 | 2004 | 11 | 0.060 |
Why?
|
| Oxonic Acid | 1 | 2004 | 31 | 0.060 |
Why?
|
| Tegafur | 1 | 2004 | 39 | 0.060 |
Why?
|
| Tetracyclines | 1 | 2004 | 64 | 0.060 |
Why?
|
| Physiological Phenomena | 1 | 2004 | 18 | 0.060 |
Why?
|
| Adenoviruses, Human | 1 | 2006 | 255 | 0.060 |
Why?
|
| Aged, 80 and over | 16 | 2006 | 58952 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 2004 | 0.060 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2004 | 68 | 0.060 |
Why?
|
| Wales | 1 | 2003 | 87 | 0.060 |
Why?
|
| Female | 50 | 2008 | 392544 | 0.060 |
Why?
|
| Humans | 64 | 2014 | 761208 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2014 | 2220 | 0.060 |
Why?
|
| Lung Neoplasms | 4 | 2004 | 13385 | 0.060 |
Why?
|
| Benzoquinones | 1 | 2004 | 198 | 0.060 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2003 | 86 | 0.050 |
Why?
|
| Sterols | 1 | 2003 | 64 | 0.050 |
Why?
|
| Stilbenes | 1 | 2004 | 155 | 0.050 |
Why?
|
| Radioligand Assay | 1 | 2003 | 366 | 0.050 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2003 | 83 | 0.050 |
Why?
|
| Neoplasm Metastasis | 4 | 2006 | 4909 | 0.050 |
Why?
|
| Adenosylmethionine Decarboxylase | 1 | 2002 | 11 | 0.050 |
Why?
|
| Mucin-1 | 2 | 2004 | 538 | 0.050 |
Why?
|
| Lactates | 1 | 2003 | 401 | 0.050 |
Why?
|
| Lactams, Macrocyclic | 1 | 2004 | 318 | 0.050 |
Why?
|
| Gene Frequency | 3 | 2003 | 3603 | 0.050 |
Why?
|
| Dioxolanes | 1 | 2002 | 23 | 0.050 |
Why?
|
| Sulfonylurea Compounds | 1 | 2003 | 219 | 0.050 |
Why?
|
| Isotope Labeling | 1 | 2003 | 393 | 0.050 |
Why?
|
| Polyamines | 1 | 2002 | 133 | 0.050 |
Why?
|
| Time Factors | 12 | 2006 | 39957 | 0.050 |
Why?
|
| Deoxycytidine | 2 | 2003 | 878 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 750 | 0.050 |
Why?
|
| Phthalazines | 1 | 2004 | 383 | 0.050 |
Why?
|
| Butyrates | 1 | 2002 | 169 | 0.050 |
Why?
|
| Morpholines | 1 | 2004 | 581 | 0.050 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2004 | 422 | 0.050 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 1869 | 0.050 |
Why?
|
| Leukemia, Experimental | 1 | 2001 | 225 | 0.050 |
Why?
|
| Urea | 1 | 2003 | 442 | 0.050 |
Why?
|
| Thalidomide | 1 | 2006 | 885 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2004 | 664 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 2571 | 0.050 |
Why?
|
| Cytosine | 1 | 2002 | 212 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 4 | 2004 | 9187 | 0.040 |
Why?
|
| Quinolones | 1 | 2003 | 378 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2004 | 2263 | 0.040 |
Why?
|
| Diarrhea | 5 | 2006 | 1316 | 0.040 |
Why?
|
| Pyrroles | 1 | 2006 | 1124 | 0.040 |
Why?
|
| Colorectal Neoplasms | 3 | 2005 | 6919 | 0.040 |
Why?
|
| Uridine | 1 | 2000 | 135 | 0.040 |
Why?
|
| Pyrazolones | 1 | 1999 | 8 | 0.040 |
Why?
|
| Anthraquinones | 1 | 1999 | 41 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2000 | 210 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2003 | 935 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2001 | 714 | 0.040 |
Why?
|
| Thrombocytopenia | 5 | 2006 | 1182 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 2000 | 389 | 0.040 |
Why?
|
| Retinal Diseases | 1 | 2004 | 705 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 1999 | 374 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2001 | 561 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 1404 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2006 | 1301 | 0.040 |
Why?
|
| Isoxazoles | 1 | 1999 | 233 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2003 | 8003 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2005 | 1838 | 0.040 |
Why?
|
| Melanoma | 2 | 2006 | 5694 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2003 | 1187 | 0.030 |
Why?
|
| Vomiting | 4 | 2000 | 650 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2004 | 2916 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 2010 | 0.030 |
Why?
|
| Europe | 1 | 2003 | 3423 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1998 | 359 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2003 | 4739 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2004 | 5321 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 563 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2002 | 1264 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2000 | 1642 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2006 | 5662 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2000 | 3605 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2004 | 2553 | 0.030 |
Why?
|
| Cell Division | 1 | 2001 | 4451 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2003 | 2683 | 0.030 |
Why?
|
| Skin | 2 | 2006 | 4473 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 6124 | 0.030 |
Why?
|
| Brain Edema | 1 | 1998 | 604 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 2478 | 0.030 |
Why?
|
| Carcinoma | 1 | 2004 | 2330 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2004 | 2477 | 0.030 |
Why?
|
| Retina | 1 | 2004 | 2655 | 0.030 |
Why?
|
| DNA | 2 | 2006 | 7189 | 0.030 |
Why?
|
| Medical Audit | 1 | 2014 | 452 | 0.030 |
Why?
|
| Leukemia | 1 | 2001 | 1518 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2001 | 2925 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2000 | 2381 | 0.030 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2014 | 344 | 0.030 |
Why?
|
| Carbazoles | 2 | 2005 | 220 | 0.020 |
Why?
|
| Follow-Up Studies | 5 | 2006 | 39126 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2004 | 3027 | 0.020 |
Why?
|
| Carboplatin | 2 | 2006 | 793 | 0.020 |
Why?
|
| Protein Binding | 1 | 2004 | 9297 | 0.020 |
Why?
|
| Animals | 5 | 2004 | 168079 | 0.020 |
Why?
|
| Neutrophils | 1 | 2004 | 3763 | 0.020 |
Why?
|
| Statistics, Nonparametric | 3 | 2002 | 2854 | 0.020 |
Why?
|
| Biopsy | 2 | 2004 | 6781 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2001 | 2915 | 0.020 |
Why?
|
| Dexamethasone | 1 | 1998 | 1945 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2004 | 5300 | 0.020 |
Why?
|
| Piperidines | 1 | 1998 | 1656 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1998 | 1520 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 3594 | 0.020 |
Why?
|
| Glucosides | 2 | 2005 | 512 | 0.020 |
Why?
|
| Drug Combinations | 2 | 2005 | 2048 | 0.020 |
Why?
|
| Immunohistochemistry | 4 | 2004 | 11067 | 0.020 |
Why?
|
| Drug Eruptions | 2 | 2002 | 335 | 0.020 |
Why?
|
| Pyrazoles | 1 | 1999 | 2010 | 0.020 |
Why?
|
| Fatigue | 2 | 2006 | 1550 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 6341 | 0.020 |
Why?
|
| Asthenia | 1 | 2006 | 16 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2001 | 1535 | 0.020 |
Why?
|
| Mice | 3 | 2004 | 81326 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1998 | 4190 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2005 | 20588 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2006 | 204 | 0.020 |
Why?
|
| Orotate Phosphoribosyltransferase | 1 | 2004 | 5 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2006 | 525 | 0.010 |
Why?
|
| Neoplasm Staging | 3 | 2006 | 11119 | 0.010 |
Why?
|
| Bilirubin | 1 | 2006 | 436 | 0.010 |
Why?
|
| Treatment Outcome | 7 | 2006 | 64681 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2001 | 4872 | 0.010 |
Why?
|
| Farnesyltranstransferase | 1 | 2003 | 71 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2004 | 464 | 0.010 |
Why?
|
| Protein Prenylation | 1 | 2003 | 70 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2005 | 282 | 0.010 |
Why?
|
| Intercalating Agents | 1 | 2003 | 33 | 0.010 |
Why?
|
| Tablets | 1 | 2003 | 148 | 0.010 |
Why?
|
| Benzofurans | 1 | 2003 | 139 | 0.010 |
Why?
|
| HLA-B27 Antigen | 1 | 2002 | 63 | 0.010 |
Why?
|
| Vitamin B 12 | 1 | 2006 | 524 | 0.010 |
Why?
|
| Amidines | 1 | 2002 | 29 | 0.010 |
Why?
|
| Patient Selection | 2 | 2006 | 4246 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 7407 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2006 | 1875 | 0.010 |
Why?
|
| Edema | 1 | 2006 | 764 | 0.010 |
Why?
|
| Electroretinography | 1 | 2004 | 524 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 392 | 0.010 |
Why?
|
| Indans | 1 | 2002 | 92 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 11101 | 0.010 |
Why?
|
| Evoked Potentials, Visual | 1 | 2004 | 417 | 0.010 |
Why?
|
| Survival Analysis | 2 | 2004 | 10088 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2014 | 8642 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2002 | 611 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 3803 | 0.010 |
Why?
|
| Biological Availability | 1 | 2001 | 389 | 0.010 |
Why?
|
| Phenylurea Compounds | 1 | 2003 | 529 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2006 | 709 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2003 | 341 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2004 | 1391 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 2006 | 1156 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2000 | 72 | 0.010 |
Why?
|
| Exanthema | 1 | 2004 | 503 | 0.010 |
Why?
|
| Phenylbutyrates | 1 | 2000 | 72 | 0.010 |
Why?
|
| Mutation | 1 | 2004 | 30002 | 0.010 |
Why?
|
| Solubility | 1 | 2001 | 1085 | 0.010 |
Why?
|
| Cytoprotection | 1 | 2000 | 200 | 0.010 |
Why?
|
| Tyrosine | 1 | 2003 | 1422 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 629 | 0.010 |
Why?
|
| Folic Acid | 1 | 2006 | 1323 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2004 | 36415 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1999 | 178 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2004 | 1553 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2014 | 4795 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 1603 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 1240 | 0.010 |
Why?
|
| Vitamins | 1 | 2007 | 1634 | 0.010 |
Why?
|
| Acetates | 1 | 2000 | 319 | 0.010 |
Why?
|
| ras Proteins | 1 | 2003 | 1055 | 0.010 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 1998 | 105 | 0.010 |
Why?
|
| Headache | 1 | 2006 | 1255 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2000 | 459 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 3778 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 1151 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2004 | 20982 | 0.010 |
Why?
|
| Feasibility Studies | 2 | 1999 | 5250 | 0.010 |
Why?
|
| Visual Fields | 1 | 2004 | 1059 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 7400 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 6312 | 0.010 |
Why?
|
| Haplotypes | 1 | 2003 | 2715 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2004 | 1985 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2000 | 1756 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2000 | 631 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 3388 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1998 | 9025 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 3057 | 0.010 |
Why?
|
| Adrenalectomy | 1 | 1998 | 346 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1998 | 552 | 0.010 |
Why?
|
| Quinolines | 1 | 2000 | 764 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2006 | 3493 | 0.010 |
Why?
|
| Immunoconjugates | 1 | 2003 | 963 | 0.010 |
Why?
|
| Anemia | 1 | 2004 | 1504 | 0.010 |
Why?
|
| Pyrazines | 1 | 2000 | 1202 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 4340 | 0.010 |
Why?
|
| Biphenyl Compounds | 1 | 2000 | 1007 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 3149 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 5773 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2004 | 2465 | 0.010 |
Why?
|
| Antibodies | 1 | 2002 | 2415 | 0.010 |
Why?
|
| Hospitalization | 1 | 2014 | 10707 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 4111 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2004 | 1457 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2002 | 11509 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 4618 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2007 | 3410 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 1201 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 8300 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2003 | 6819 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2002 | 2426 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 24021 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 6223 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2007 | 41496 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 6345 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 12404 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 13402 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2001 | 2911 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 17598 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2000 | 2092 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1998 | 1818 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 13511 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 12747 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2003 | 23416 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 8998 | 0.000 |
Why?
|
| Liver | 1 | 2003 | 7514 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1998 | 12341 | 0.000 |
Why?
|
| Survival Rate | 1 | 1998 | 12728 | 0.000 |
Why?
|
| Adolescent | 1 | 2003 | 88298 | 0.000 |
Why?
|
| Heart Failure | 1 | 1999 | 11701 | 0.000 |
Why?
|